For MeMo® transgenic mice for single light chain (sLC) human monoclonal antibodies, a worldwide, non-exclusive license is available. Target restrictions do not apply.
Merus is interested in strategic collaborations with pharmaceutical companies with a strong background in therapeutic monoclonal antibodies and an interest in the principal fields of application of bispecific antibodies and Oligoclonics™ antibody formats in oncology, chronic inflammation and infectious diseases. For further inquiry, please contact us through:
T. Logtenberg. Ph.D
CEO, Merus BV
Padualaan 8
3584 CH Utrecht
The Netherlands